A Phase II Prospective Immune Neoadjuvant Therapy Study od Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IONESCO
- 24 Apr 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 24 Apr 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 08 Mar 2017 Status changed from not yet recruiting to recruiting.